3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?

被引：14

作者：

Tang, Kenny ^{[1
]}

Schuh, Andre C. ^{[1
]}

Yee, Karen W. L. ^{[1
]}

机构：

[1] Univ Hlth Network, Princess Margaret Canc Ctr, Div Med Oncol & Hematol, 610 Univ Ave,700 U 6th Floor, Toronto, ON M5G 2M9, Canada

来源：

CURRENT ONCOLOGY REPORTS | 2021年 / 23卷 / 10期

关键词：

Acute myeloid leukemia; cytarabine; CPX-351; Daunorubicin; Midostaurin; gemtuzumab ozogamicin; Venetoclax; INTERNAL TANDEM DUPLICATION; CONVENTIONAL CARE REGIMENS; HIGH-DOSE DAUNORUBICIN; OLDER PATIENTS; GEMTUZUMAB OZOGAMICIN; ADULT PATIENTS; OPEN-LABEL; INDUCTION CHEMOTHERAPY; PROGNOSTIC RELEVANCE; ELDERLY-PATIENTS;

D O I：

10.1007/s11912-021-01108-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose of Review With the recent approval of multiple new drugs for the treatment of acute myeloid leukemia (AML), the relevance of conventional treatment approaches, such as daunorubicin and cytarabine ("3+7") induction chemotherapy, has been challenged. We review the AML risk stratification, the efficacy of the newly approved drugs, and the role of "3+7". Recent Findings Treatment of AML is becoming more niched with specific subtypes more appropriately treated with gemtuzumab, midostaurin, and CPX-351. Although lower intensity therapies can yield high response rates, they are less efficient at preventing relapses. The only curative potential for poor-risk AML is still an allogeneic stem cell transplant. The number of AML subtypes where 3+7 alone is an appropriate therapeutic option is shrinking. However, it remains the backbone for combination therapy with newer agents in patients suitable for intensive chemotherapy.

引用

页数：13

共 90 条

[1]

[Anonymous], Acute Myeloid Leukemia (Version 3.2022)

[2] The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [J].

Arber, Daniel A. ;

Orazi, Attilio ;

Hasserjian, Robert ;

Thiele, Jurgen ;

Borowitz, Michael J. ;

Le Beau, Michelle M. ;

Bloomfield, Clara D. ;

Cazzola, Mario ;

Vardiman, James W. .

BLOOD, 2016, 127 (20) :2391-2405

[3] Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia [J].

Arslan, Shukaib ;

Zhang, Jianying ;

Dhakal, Prajwal ;

Moran, Jenna ;

Naidoo, Nuthana ;

Lombardi, Jennifer ;

Pullarkat, Vinod ;

Stein, Anthony S. ;

Marcucci, Guido ;

Yaghmour, George ;

Bhatt, Vijaya R. ;

Fathi, Amir T. ;

Aldoss, Ibrahim .

AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (03) :E59-E63

[4] Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: a retrospective study from the Acute Leukemia Working Party of the EBMT [J].

Battipaglia, G. ;

Labopin, M. ;

Candoni, A. ;

Fanin, R. ;

El Cheikh, J. ;

Blaise, D. ;

Michallet, M. ;

Ruggeri, A. ;

Contentin, N. ;

Ribera, J. M. ;

Stadler, M. ;

Sierra, J. ;

Borne, P. A. von Dem ;

Bloor, A. ;

Socie, G. ;

Nagler, A. ;

Mohty, M. .

BONE MARROW TRANSPLANTATION, 2017, 52 (04) :592-599

[5] Outcomes After Induction Chemotherapy in Patients With Acute Myeloid Leukemia Arising From Myelodysplastic Syndrome [J].

Bello, Celeste ;

Yu, Daohai ;

Komrokji, Rami S. ;

Zhu, Weiwei ;

Wetzstein, Gene A. ;

List, Alan F. ;

Lancet, Jeffrey E. .

CANCER, 2011, 117 (07) :1463-1469

[6] Co-occurrence of DNMT3A, NPM1, FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis [J].

Bezerra, Matheus F. ;

Lima, Aleide S. ;

Pique-Borras, Maria-Riera ;

Silveira, Douglas R. ;

Coelho-Silva, Juan L. ;

Pereira-Martins, Diego A. ;

Weinhauser, Isabel ;

Franca-Neto, Pedro L. ;

Quek, Lynn ;

Corby, Anna ;

Oliveira, Mayara M. ;

Lima, Marinus M. ;

de Assis, Reijane A. ;

Campos, Paula de Melo ;

Duarte, Bruno K. ;

Bendit, Israel ;

Rocha, Vanderson ;

Rego, Eduardo M. ;

Traina, Fabiola ;

Saad, Sara T. ;

Beltrao, Eduardo I. ;

Bezerra, Marcos A. ;

Lucena-Araujo, Antonio R. .

BLOOD, 2020, 135 (11) :870-875

[7]

Bhella S.D., 2015, ASH ANN M, V126, P4893, DOI DOI 10.1182/BLOOD.V126.23.4893.4893

[8]

Buchner T, 1997, BLOOD S, V90, p583a

[9] Genomics of Acute Myeloid Leukemia Diagnosis and Pathways [J].

Bullinger, Lars ;

Doehner, Konstanze ;

Doehner, Hartmut .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (09) :934-946

[10] A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment [J].

Burnett, Alan K. ;

Milligan, Donald ;

Prentice, Archie G. ;

Goldstone, Anthony H. ;

McMullin, Mary F. ;

Hills, Robert K. ;

Wheatley, Keith .

CANCER, 2007, 109 (06) :1114-1124

← 1 2 3 4 5 6 7 8 9 →